Cerenome, Inc.
Research Cerenome, Inc. (CNSY) on Bullrun: market cap USD 4.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCNSY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.68M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 9.01M
- Free cash flow-USD 7.63M
Valuation Snapshot
latest market cap is USD 4.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.39M | -USD 20.84M | n/a | -7.25 | USD 4.26M | USD 821.00K | USD 4.00M |
| FY2024 | USD 0 | -USD 12.98M | -USD 11.25M | n/a | -58.5 | USD 76.00K | USD 3.37M | -USD 8.95M |
| FY2023 | USD 0 | -USD 13.32M | -USD 13.01M | n/a | -106 | USD 8.55M | USD 4.18M | -USD 1.35M |
| FY2022 | USD 0 | -USD 20.28M | -USD 13.73M | n/a | -288.75 | USD 18.12M | USD 5.65M | USD 6.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 4.68M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 70.72M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.78M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 197.87M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 260.56M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 407.14M | n/a | n/a | n/a |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cerenome, Inc.'s market cap?
Cerenome, Inc.'s market capitalization is USD 4.68M.
What does Cerenome, Inc. do?
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection.